EAM Investors’s CG Oncology CGON Stock Holding History

EAM Investors’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-46,102	Closed	-$3.12M	–	287
2026 Q1	$3.12M	Buy	+46,102	New	+$2.61M	0.36%	135

Other funds holding CGON

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EAM Investors's CGON Position: Q2 2026 in Review

EAM Investors sold out of CG Oncology (CGON) in Q2 2026, closing a stake of 46,102 shares — an estimated $3.12M sold.

EAM Investors first reported a position in CGON in Q1 2026 and held it in 1 quarter. The position peaked at $3.12M in Q1 2026. 228 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

EAM Investors reported no remaining CG Oncology position as of Q2 2026 after selling out during the quarter.
EAM Investors sold 46,102 CG Oncology shares in Q2 2026, an estimated $3.12M.
EAM Investors first reported a position in CG Oncology in Q1 2026 and held it in 1 quarter.
EAM Investors's CG Oncology position peaked at $3.12M in Q1 2026.
228 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.